Early 18F‐labeled fluoro‐2‐deoxy‐D‐glucose positron emission tomography scanning in the lymphomas
Open Access
- 18 September 2006
- Vol. 107 (7), 1425-1428
- https://doi.org/10.1002/cncr.22178
Abstract
The identification of refractory or nonresponding tumors at an early period during therapy may lead to abbreviation of the current therapy regimen or timely institution of an alternative therapy protocol. Nevertheless, evaluation of treatment response is consequential clinically if the tumor potentially is curable and if effective treatment alternatives exist, so that change in treatment ultimately may increase the probability of response and survival. Hodgkin disease (HD) and diffuse large cell lymphoma (LCL) fit in this model well. However, a subset of patients is either refractory to first-line treatment or develops recurrent disease after an initial remission. Improvements in the treatment of these diseases rely not only on new therapy modalities and accurate assessment of disease extent but also on the assessment of disease extent and on timely and accurate therapy response to enable a more effective management plan. Although the International Prognostic Score for HD and International Prognostic Index for LCL have proved valuable for the stratification of patients in clinical trials, there is variability in outcome within the individual risk groups. Recently, positron emission tomography using 18F-labeled fluoro-2-deoxy-D-glucose (FDG-PET) imaging has been suggested as a sensitive and relatively more specific means to reflect tumor biologic changes after therapy. With increasingly compelling evidence, early FDG-PET provides a reliable means to assess tumor response accurately that may lead to better management with an effective therapeutic approach. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 28 references indexed in Scilit:
- Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin diseaseBlood, 2004
- Current strategies for early Hodgkin's diseaseAnnals of Oncology, 1996
- The Case Against the Routine Use of Radiation Therapy in Advanced-Stage Hodgkin's DiseaseCancer Investigation, 1996
- Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review.Journal of Clinical Oncology, 1994
- Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's LymphomaThe New England Journal of Medicine, 1993
- Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: Updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapyAnnals of Oncology, 1991
- Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.Journal of Clinical Oncology, 1988
- Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions.Journal of Clinical Oncology, 1986
- Restaging laparotomy in the management of the non-Hodgkin lymphomasMedical and Pediatric Oncology, 1982
- Chemotherapy of the Non-Hodgkin's LymphomasMedical Clinics of North America, 1976